Business
Pfizer to halt biosimilar output in China, sell assets to WuXi Biologics
Published by linker 5
Posted on March 17, 2021
· Last updated: January 21, 2026
Related Articles
The Trust Economy: Why Reputation Is Becoming the Ultimate Currency
The Speed Illusion: Why Faster Decisions Don’t Always Win
The Resilience Premium: Why Stability Is Becoming More Valuable Than Growth
The Profit Paradox: Why Growth No Longer Guarantees Value
The Platform Effect: Why Businesses Are Becoming Ecosystems by Default
More from Business
Explore more articles in the Business category
The New Middle: Why Mid-Sized Companies Are Quietly Winning
The Decision Economy: How Data Is Changing Who Really Holds Power
The Experience Gap: Why Customer Satisfaction Is No Longer Enough
The Hidden Edge Driving Business Success
Beyond Scale: How Precision Strategy Is Replacing Mass Expansion
Price Isn’t Everything: Payment Options a Deciding Factor for B2B Buyers in Europe
The Optionality Trap—Why Too Much Flexibility Is Slowing Business Decisions
Why More Choices Are Slowing Businesses Down
Why More Output Isn’t Translating Into Better Results
The Reversibility Problem—Why Businesses Hesitate Even When They Know the Answer
The Alignment Illusion—Why Companies Agree on Strategy but Fail in Execution
Attention Is the New Competitive Advantage